BriaCell Therapeutics has successfully priced a best-efforts offering of 5,366,726 units, raising gross proceeds of approximately $30 million before fees and expenses. Each unit comprises one common share (or a pre-funded warrant in lieu thereof) and one warrant, with the warrants approved for listing on the Nasdaq Capital Market under the symbol “BCTXL” beginning January 14, 2026. Each warrant is immediately exercisable, entitles the holder to one common share and has a five-year term. The offering, expected to close on January 15, 2026, is being led by ThinkEquity as sole placement agent, and the company intends to deploy net proceeds toward working capital, general corporate purposes and advancement of its immunotherapy programs.

In the Phase 1/2a study of Bria-OTS, BriaCell’s off-the-shelf personalized immunotherapy for metastatic breast cancer, a 78-year-old HR+/HER2– patient achieved a sustained complete response of a lung metastasis after four monotherapy doses. This 100% tumor resolution was first confirmed at two months and has now persisted through 11 months of follow-up. The patient received 17 treatment cycles and remains in survival follow-up with stable disease at all other evaluable sites and no treatment-limiting toxicities. With dose escalation complete, the Phase 2a portion is now evaluating Bria-OTS in combination with an immune checkpoint inhibitor.

BriaCell filed its registration statement on Form S-1 with the U.S. Securities and Exchange Commission in December 2025, which became effective on January 13, 2026, alongside a related Rule 462(b) filing. The company is relying on an exemption under Section 602.1 of the TSX Company Manual to proceed with its interlisted transaction on Nasdaq without additional TSX standards. These regulatory steps, combined with the financing, are designed to bolster the company’s balance sheet and support rapid advancement of its lead immunotherapy candidates through ongoing and planned clinical trials.